DNA vaccines: the story so far… & the next chapter

Vaccine Insights 2023; 2(1), 15–19

DOI: 10.18609/vac.2023.004

Published: 22 February
Michele Kutzler

Charlotte Barker Editor, Vaccine Insights, talks to Michele Kutzler, Associate Dean for Faculty, Professor of Medicine and Microbiology & Immunology, Drexel University College of Medicine

Michele Kutzler is a Professor of Medicine and Microbiology and Immunology at Drexel University College of Medicine. After completing a PhD in microbiology and immunology at Lewis Katz School of Medicine at Temple University, Philadelphia, Pennsylvania, USA, and a post-doctoral research fellowship in gene therapy and vaccines at Perelman School of Medicine at the University of Pennsylvania, Philadelphia, Pennsylvania, she joined Drexel University College of Medicine in the Division of Infectious Diseases & HIV Medicine. Dr Kutzler works to develop nucleic acid-based prophylactic vaccine strategies against pathogens including Human Immunodeficiency Virus, the bacterium Clostridioides difficile, and more recently, SARS-CoV2. Her expertise is in the use of nucleic acid-based antigenic platforms and molecular immunoadjuvant systems to boost immune durability and enhance the quality of immune responses to vaccines, particularly in the elderly.

Michele Kutzler discusses her career in vaccine research, the roadblocks that have, until recently, kept DNA vaccines out of the clinic, and why she believes a happy ending is in sight for the platform.